CalciMedica, Inc. (CALC)

CalciMedica's stock price was significantly impacted by the discontinuation of the Phase 2 KOURAGE trial for Auxora in AKI due to safety concerns, leading to a substantial drop in stock value. The company reported 2025 financial results and clinical updates in March 2026, confirming no drug-related toxicity with Auxora and discussing future clinical studies with the FDA. CalciMedica received Nasdaq deficiency notices and its stock price has decreased by 90.5% since the start of the year.

As a clinical-stage biopharmaceutical company, CalciMedica's products are not yet commercialized, so there is no traditional demand seasonality for its products and services. The company's focus is on advancing its drug candidates through clinical trials and regulatory approvals.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunologic diseases by inhibiting CRAC channels. Their lead product candidate, Auxora, is being developed for conditions like acute pancreatitis, acute kidney injury, and severe COVID-19 pneumonia. They also have CM5480, a next-generation CRAC channel inhibitor for chronic dosing, potentially for pulmonary arterial hypertension.

CalciMedica, Inc. is headquartered in La Jolla, California, and operates as one segment, focusing on the development and commercialization of its therapeutics primarily within the U.S.

CalciMedica's brand reputation was negatively impacted by the discontinuation of the Phase 2 KOURAGE trial, leading to a stock price drop and investor concerns. The company has worked to clarify that no drug-related toxicity was identified in reviews of the data. Analyst consensus currently rates CalciMedica as a "Hold."

CalciMedica has minimal institutional ownership, with a significant portion (41.55%) held by insiders. The ownership structure includes Venture Capital, Individual Investors, Investment Advisors/Hedge Funds, Corporations, and Research Firms.